News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,034 Results
Type
Article (1803)
Company Profile (2)
Press Release (6229)
Multimedia
Podcasts (18)
Webinars (1)
Section
Business (2460)
Career Advice (55)
Deals (526)
Drug Delivery (12)
Drug Development (1523)
Employer Resources (15)
FDA (287)
Job Trends (495)
News (4533)
Policy (500)
Tag
Academia (37)
Accelerated approval (2)
Adcomms (1)
Allergies (1)
Alliances (526)
ALS (6)
Alzheimer's disease (45)
Antibody-drug conjugate (ADC) (17)
Approvals (279)
Artificial intelligence (10)
Autoimmune disease (6)
Bankruptcy (2)
Best Places to Work (406)
BIOSECURE Act (1)
Biosimilars (43)
Biotechnology (1)
Brain cancer (1)
Cancer (124)
Cardiovascular disease (5)
Career advice (43)
Career pathing (1)
CAR-T (6)
CDC (1)
Cell therapy (23)
Clinical research (1288)
Collaboration (38)
Complete response letters (3)
COVID-19 (51)
C-suite (30)
Cystic fibrosis (4)
Data (108)
Denatured (3)
Depression (13)
Diabetes (4)
Diagnostics (38)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (26)
Drug shortages (2)
Duchenne muscular dystrophy (2)
Earnings (908)
Editorial (5)
Employer branding (7)
Employer resources (12)
Events (1153)
Executive appointments (24)
FDA (340)
Frontotemporal dementia (1)
Funding (27)
Gene editing (2)
Gene therapy (22)
GLP-1 (44)
Government (136)
Guidances (6)
Healthcare (130)
Huntington's disease (5)
IgA nephropathy (1)
Immunology and inflammation (32)
Immuno-oncology (2)
Indications (3)
Infectious disease (60)
Inflammatory bowel disease (15)
Inflation Reduction Act (1)
Interviews (6)
IPO (224)
IRA (6)
Job creations (86)
Job search strategy (41)
JPM (9)
Labor market (5)
Layoffs (27)
Legal (134)
Longevity (1)
Lung cancer (6)
Lymphoma (49)
Management (2)
Manufacturing (23)
MASH (2)
Medical device (37)
Medtech (37)
Mergers & acquisitions (330)
Metabolic disorders (29)
Multiple sclerosis (2)
Neurodegenerative disease (24)
Neuropsychiatric disorders (12)
Neuroscience (111)
NextGen: Class of 2026 (107)
Non-profit (39)
Now hiring (45)
Obesity (22)
Opinion (18)
Ovarian cancer (10)
Pain (3)
Pancreatic cancer (1)
Parkinson's disease (17)
Partnered (1)
Patents (13)
Patient recruitment (2)
People (898)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase 1 (377)
Phase 2 (501)
Phase 3 (678)
Pipeline (94)
Policy (19)
Postmarket research (24)
Preclinical (89)
Prostate cancer (2)
Psychedelics (9)
Radiopharmaceuticals (1)
Rare diseases (20)
Real estate (53)
Recruiting (8)
Regulatory (363)
Reports (1)
Research institute (43)
Resumes & cover letters (5)
RNA editing (2)
RSV (6)
Schizophrenia (25)
Series A (9)
Series B (3)
Sickle cell disease (1)
Special edition (2)
Startups (66)
Supply chain (1)
Tariffs (14)
The Weekly (14)
Vaccines (13)
Venture capital (10)
Weight loss (17)
Worklife (1)
Date
Today (4)
Last 7 days (11)
Last 30 days (64)
Last 365 days (555)
2026 (64)
2025 (558)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Arizona (3)
Asia (422)
Australia (46)
California (209)
Canada (36)
China (11)
Colorado (4)
Connecticut (5)
Delaware (1)
Europe (1300)
Florida (9)
Georgia (5)
Illinois (123)
India (9)
Indiana (10)
Iowa (1)
Japan (8)
Maryland (9)
Massachusetts (127)
Michigan (1)
Minnesota (3)
Missouri (1)
Nebraska (1)
New Hampshire (1)
New Jersey (36)
New York (31)
North Carolina (8)
Northern California (57)
Ohio (5)
Oregon (1)
Pennsylvania (26)
Rhode Island (1)
South America (27)
South Carolina (1)
Southern California (127)
Tennessee (8)
Texas (9)
United States (560)
Utah (2)
Virginia (8)
Washington D.C. (7)
Washington State (4)
Wisconsin (2)
8,034 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Cancer
JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
January 14, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions
AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.
January 13, 2026
·
2 min read
·
Tristan Manalac
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Layoffs
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.
November 13, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
Psychedelics Space Enters New Era as AbbVie Dives In
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
September 22, 2025
·
6 min read
·
Heather McKenzie
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted.
September 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
January 29, 2026
·
5 min read
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
1 of 804
Next
